Research
Hormonal
GLP-1 receptor agonists should be discontinued immediately upon confirmation of pregnancy due to the lack of approved safety data, despite current evidence not showing teratogenicity.
Stop taking your GLP-1 medication as soon as you get a positive pregnancy test. Your doctor will likely switch you to insulin or diet management to keep your blood sugar stable, which is the standard of care for diabetes in pregnancy.
GoodSupportsHIGH confidence
Currently, Glucagon-like peptide-1 receptor agonists should be stopped as soon as the patient becomes aware of a pregnancy.
Why this rating
Based on the precautionary principle due to lack of large-scale planned pregnancy data.
Source
Glucagon‐like peptide 1 ( <scp>GLP</scp> ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
Claire Parker et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16437
narrative_review · n=32598Cited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →